



Tobacco industry ownership of pharmaceutical companies patient survey



The COPD Foundation, along with global partners, surveyed people with chronic respiratory disease. The survey gave the patient community a voice in the conversation about tobacco corporations owning companies that develop tools and medications to treat lung conditions.

1,196

People with respiratory disease surveyed



70% were "bothered" or "really bothered" by a tobacco company making an inhaler to treat lung conditions.


Respondent Information

English
86.4%




German 2.2% Spanish 11.4%

Reported Conditions




Former smoker
73.1%



Willing to switch to a treatment that tobacco companies do not fund

48%



The COPD Foundation believes patients deserve and desire the right for transparency about their medications. Shared decision making between patients and clinicians will allow for choosing the best plan for each individual.

Notes: Complete survey was only available to those who indicated inhaler use. Reported conditions may include multiple selections by respondents. *Other includes: Alpha-1 antitrypsin deficiency, NTM lung diseases, ILD, EGPA, etc.
Sources: Tal-Singer R., Walsh L., et al., "Tobacco industry ownership of pharmaceutical companies: an international survey of people with respiratory disease," *Thorax*, 2022, doi: <https://dx.doi.org/10.1136/thorax-2022-219142>.
 Tal-Singer, R, et al., (2022, August 4) Late Breaking Abstract - Patient sentiments on tobacco industry ownership of respiratory therapies: A community survey [Presentation] ERS International Congress 2022, Barcelona, Spain.